US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Provident

16.64

+0.11000.67%

Post-market: 16.640.00000.00%16:20 EDT

Volume:538.67K

Turnover:8.95M

Market Cap:2.17B

PE:14.01

High:16.70

Open:16.45

Low:16.40

Close:16.53

Loading ...

Overview Company News Filings

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

March 2025 Value Equities That Could Be Trading Below Estimated Worth

Simply Wall St.

Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Resources Top 5: At last, something for lithium stocks to shout from the rooftops

Arizona Lithium welcomes Canadian critical minerals reforms

New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings

3 Stocks Estimated To Be Trading At Discounts Of Up To 47%

Simply Wall St.

Provident Bank Announces $950,000 in NRTC Funding Awards to Ten New Jersey Non-Profit Organizations

Three Stocks Trading Below Estimated Value In March 2025

Simply Wall St.

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study

MT Newswires Live

Press Release: CARsgen Announced 2024 Annual Results

Press Release: OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Top 3 Dividend Stocks To Consider For Your Portfolio

Simply Wall St.

INAB: Introducing INB-600, A γδ T Cell Engager Platform

Zacks Small Cap Research

ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients

Discover TSX Penny Stocks: Lion Copper and Gold Plus 2 More Hidden Gems

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/PFS/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PFS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident","latestPrice":16.64,"timestamp":1745956800000,"preClose":16.53,"halted":0,"volume":538666,"hourTrading":{"tag":"盘后","latestPrice":16.64,"preClose":16.64,"latestTime":"16:20 EDT","volume":42938,"amount":714488.32,"timestamp":1745958000438},"delay":0,"floatShares":126167377,"shares":130663184,"eps":1.188092,"marketStatus":"Not Yet Opened","change":0.11,"latestTime":"04-29 16:00:00 EDT","open":16.45,"high":16.695,"low":16.395,"amount":8948762.730697,"amplitude":0.018149,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.188092,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746000000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":16.53,"dividendRate":0.057692,"preHourTrading":{"tag":"盘前","latestPrice":16.53,"preClose":16.53,"latestTime":"08:02 EDT","volume":2,"amount":33,"timestamp":1745928175006},"postHourTrading":{"tag":"盘后","latestPrice":16.64,"preClose":16.64,"latestTime":"16:20 EDT","volume":42938,"amount":714488.32,"timestamp":1745958000438},"volumeRatio":0.644314,"impliedVol":0.0617,"impliedVolPercentile":0.0924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PFS\",,,,,undefined,":{"symbol":"PFS","floatShares":126167377,"roa":"0.77%","roe":"6.77%","lyrEps":1.053397,"volumeRatio":0.644314,"shares":130663184,"dividePrice":0.96,"high":16.695,"amplitude":0.018149,"preClose":16.53,"low":16.395,"week52Low":13.07,"pbRate":"0.82","psRate":"3.10","week52High":22.24,"institutionHeld":0.6698,"latestPrice":16.64,"eps":1.188092,"divideRate":0.057692,"volume":538666,"delay":0,"ttmEps":1.188092,"open":16.45,"prevYearClose":18.87,"prevWeekClose":16.54,"prevMonthClose":17.17,"prevQuarterClose":17.17,"fiveDayClose":16.01,"twentyDayClose":17.17,"sixtyDayClose":18.57},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PFS\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2522234805","title":"Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2522234805","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522234805?lang=en_us&edition=fundamental","pubTime":"2025-03-26 21:05","pubTimestamp":1742994300,"startTime":"0","endTime":"0","summary":"SON-1010 is being studied as a combination therapy with trabectedin (Yondelis), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, d","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/26/3049745/0/en/Sonnet-BioTherapeutics-Successfully-Completes-First-Safety-Review-of-SON-1010-in-Combination-with-Trabectedin-in-Certain-Sarcomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","BK4139","SON","BK4567","PR","MTD","BK4552","LU0347712357.USD","LU2413666426.HKD","BK4548","LU2039709279.SGD","BK4211","IE00BYQQ9H92.USD","LU1093756168.USD","PFS","PK","BK4533","BK4080","SRC","BK4007","BK4588","BK4563","BK4195","LU1023057109.AUD","PROC","01698","IE00B12V2V27.USD","PD","SG9999011746.SGD","BK4526","BK4571","SONN","BK4108","IE00BFXG0V08.USD","BK4213","LU0359201612.USD","LU2413666699.HKD","BK4121","IE00BYTNYN87.SGD","BK4136","BK4218","LU1721428933.USD","BK4181","BK4585","BK4231","BK4509","BK4023","IE00BYQNZ168.SGD","LU0359202008.SGD"],"gpt_icon":1},{"id":"2522755938","title":"March 2025 Value Equities That Could Be Trading Below Estimated Worth","url":"https://stock-news.laohu8.com/highlight/detail?id=2522755938","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522755938?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:07","pubTimestamp":1742987277,"startTime":"0","endTime":"0","summary":"As of March 2025, U.S. stock markets have been experiencing a modest recovery, with major indices like the S&P 500 and Nasdaq Composite showing slight gains after rebounding from a recent selloff driven by tariff concerns and economic uncertainty. In this environment, identifying undervalued stocks can be particularly appealing to investors looking for opportunities that may offer potential growth as the market stabilizes.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Analog Devices is trading at US$213.58, below its estimated fair value of US$260.96, suggesting it may be undervalued based on cash flows. Despite a decrease in profit margins from 24.4% to 16.7%, the company's earnings are forecast to grow significantly at 24.8% annually, outpacing the broader U.S market growth rate of 14%. Recent product innovations and strategic partnerships enhance its competitive edge, though significant insider selling raises caution about potential risks ahead.Overview: Mobiley","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/march-2025-value-equities-could-110757571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","BK4123","SGXZ23171101.USD","SW","LU0654597011.USD","BK4153","BK4157","LU2092937221.SGD","LU2401740654.USD","LU1863844749.USD","LU0053671581.USD","LU2242646235.USD","LU0471298694.HKD","LU0612318971.USD","LU0997586606.USD","BK4195","LU0205193047.USD","LU1169589451.USD","LU1169590202.USD","LU2242644610.SGD","LU2360106947.USD","LU2360108059.USD","ADI","LU2242646821.SGD","BK4124","LU1803068623.USD","SG9999004303.SGD","CSTM","LU2362541513.USD","LU0997587240.USD","BK4211","SN","LU1430597077.USD","LU1989763427.SGD","LU0048578792.EUR","HAE","KBR","IE00BLDYK493.USD","BK4198","MBLY","LU1920063259.USD","LU2380233275.USD","LU1989763690.USD","LU2041044095.USD","LU0612318385.USD","LU1892829315.USD","LU1863844665.USD","LU2298321311.HKD","BK4191","LU1119994140.HKD","LU0550127509.SGD"],"gpt_icon":0},{"id":"2522187556","title":"Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2522187556","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522187556?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:05","pubTimestamp":1742987100,"startTime":"0","endTime":"0","summary":"Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET. CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. , a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2024.Reported positive updated data from Part B of the Phase 2 DeFianCe study of sirexatamab  in second-line patients with advanced microsatellite stable  colorectal cancer  confirming:. Statistically significant 22% higherORR and 2.6 month longer PFS in patients who had not had prior anti-VEGF therapy. FL-501 abstract accepted for poster presentation at the 2025 American Association for Cancer Research  Annual Meeting.Across the intent-to-treat population, thesirexatamab Experimental Arm had improved ORR compared to the Control Arm, with PFS and OS maturing with a higher number of patients continuing to","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-fourth-quarter-110500189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CRC","BK4195","BK4141","LENZ","BK4563","BK4213","MSS","ORR","BK4505","BK4585","BK4588","BK4139","BK4543","PFS","OS","BK4609","BK4211","IE00BMPRXQ63.HKD","BK4097","IE00BMPRXR70.SGD","LU0456854461.SGD","LU0348723411.USD","IE00BMPRXN33.USD","BK4113","LPTX","LU0266512127.USD"],"gpt_icon":1},{"id":"2522596875","title":"Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2522596875","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522596875?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFSin second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy. Statistically significant 22% higher ORR and 2.6 month longer PFSin patients who had not had prioranti-VEGF therapy. Leap to host a conference call to present clinical data today, March 26, 2025, at 8:00 a.m. ET. \"The updated data from Part B of the DeFianCe study presented today confirms that sirexatamab can generate significantly higher ORR and longer PFS in CRC patients who have high levels of DKK1 or who have not had prior anti-VEGF therapy, two exploratory populations with strong scientific rationale. In the full intent-to-treat population, sirexatamab demonstrated a higher ORR and a tail population with longer PFS that continues to mature. With more sirexatamab-treated patients currently continuing on study drug than control arm patients, there is potential for the dataset to continue t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/leap-therapeutics-reports-positive-updated-110000183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","IE00BMPRXR70.SGD","LU0348723411.USD","IE00BMPRXN33.USD","BK4139","MSS","OS","BK4588","LU0456854461.SGD","LU0266512127.USD","LENZ","BK4585","LPTX","BK4211","BK4195","BK4505","BK4543","BK4097","IE00BMPRXQ63.HKD","BK4141","BK4113","ARM","CRC","BK4609","PFS","BK4563","ORR"],"gpt_icon":0},{"id":"2522877091","title":"Resources Top 5: At last, something for lithium stocks to shout from the rooftops","url":"https://stock-news.laohu8.com/highlight/detail?id=2522877091","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522877091?lang=en_us&edition=fundamental","pubTime":"2025-03-26 15:06","pubTimestamp":1742972787,"startTime":"0","endTime":"0","summary":"Canada’s critical minerals reforms have been welcomed by Arizona Lithium. European Metals’ Cinovec lithium project has been declared a Strategic Project by the EC. Bauxite and gallium have been picked up as part of an acquisition by Western Yilgarn. Your standout small cap resources stocks for Wednesday, March 26, 2025.Arizona Lithium There hasn’t been too much to shout from the rooftops in the lithium space for many months but a Canadian government critical minerals initiative is encouraging for those operating and exploring in that space in the country.The government has introduced policy reforms aimed at strengthening the country’s critical minerals sector, which, of course, includes lithium.These initiatives announced by new PM Mark Carney include measures designed to accelerate project development and investment in critical mineral supply chains.Key elements include:. streamlined project approvals through a new ‘One Project, One Review’ framework;the creation of a ‘First Mile Fund","market":"hk","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/Getty-roof-1200-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/Getty-roof-1200-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/resources/resources-top-5-something-from-lithium-to-shout-from-the-rooftops/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2522535854","title":"Arizona Lithium welcomes Canadian critical minerals reforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2522535854","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522535854?lang=en_us&edition=fundamental","pubTime":"2025-03-26 10:04","pubTimestamp":1742954652,"startTime":"0","endTime":"0","summary":"AZL welcomes new Canadian government’s critical minerals initiatives. The policies are designed to accelerate project development and investment. Company well placed to pursue phase 1 development of Prairie lithium project. Special Report: Arizona Lithium has welcomed a series of major policy reforms from the Canadian government aimed at strengthening the country’s critical minerals sector.New Canadian Prime Minister Mark Carney announced the national initiatives, which include measures designed to accelerate project development and investment in critical mineral supply chains.Key elements of the policy include:. streamlined project approvals through a new ‘One Project, One Review’ framework;the creation of a ‘First Mile Fund’ to boost early-stage investment;","market":"nz","thumbnail":"https://stockhead.com.au/wp-content/uploads/2025/03/image-1200x675-2025-03-26T090256.477-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2025/03/image-1200x675-2025-03-26T090256.477-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockhead.com.au/resources/arizona-lithium-welcomes-canadian-critical-minerals-reforms/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4195","PFS","BK4211"],"gpt_icon":0},{"id":"2522837332","title":"New study results reinforce TAGRISSO® (osimertinib) as the backbone therapy for EGFR-mutated lung cancer across stages and settings","url":"https://stock-news.laohu8.com/highlight/detail?id=2522837332","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522837332?lang=en_us&edition=fundamental","pubTime":"2025-03-26 07:02","pubTimestamp":1742943720,"startTime":"0","endTime":"0","summary":"SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity. WILMINGTON, Del., March 25, 2025----New study results presented at the European Lung Cancer Congress  2025, March 26 to 29, demonstrate the role of AstraZeneca’s TAGRISSO , as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated  non-small cell lung cancer . Highlights include:. LAURA Phase III trial of TAGRISSO in unresectable, Stage III EGFRm NSCLC after chemoradiotherapy  .SAVANNAH Phase II trial of TAGRISSO plus savolitinib in advanced EGFRm NSCLC with high levels of MET overexpression and/or amplification following disease progression on 1st-line TAGRISSO (#2O).FLAURA2 Phase III trial of TAGRISSO plus chemotherapy as 1st-line treatment for advanced EGFRm NSCLC .Professor Virginia Harrison, EGFR Positive UK, said: \"For people undergoin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/study-results-reinforce-tagrisso-osimertinib-230200995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1829250122.USD","BK4195","AZN","BK4563","LU2456880835.USD","LU0889565916.HKD","BK4503","BK4213","BK4144","BK4080","LU2462157665.USD","PFS","BK4568","CRT","LU2236285917.USD","OS","TEN","BK4166","BK4585","LU0109394709.USD","QD","BK4007","ORR","BK4588","BK4211","LU2417539215.USD","BK4124","EMM","BK4097","BK4231","LU0320765992.SGD","ADC"],"gpt_icon":1},{"id":"2522011888","title":"3 Stocks Estimated To Be Trading At Discounts Of Up To 47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522011888","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522011888?lang=en_us&edition=fundamental","pubTime":"2025-03-26 01:07","pubTimestamp":1742922479,"startTime":"0","endTime":"0","summary":"As the U.S. equities market works to extend its rebound rally, with the S&P 500 and Nasdaq showing slight gains, investors remain cautious amid ongoing concerns about tariffs and economic uncertainty. In this environment, identifying undervalued stocks can be a strategic move for investors looking to capitalize on potential discounts in the market.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Operations: The company generates revenue through its Space Systems segment, which accounts for $310.84 million, and its Launch Services segment, contributing $125.38 million.Overview: Evercore Inc. is an independent investment banking firm providing advisory services across the Americas, Europe, Middle East, Africa, and Asia-Pacific with a market cap of approximately $8.58 billion.Operations: The company's revenue is primarily derived from Investment Banking & Equities, which accounts for $2.90 billion, while Investment Management contributes $81.10 million.Evercore is curre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-stocks-estimated-trading-discounts-170759273.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0471298694.HKD","LU1917777945.USD","LU2048586759.USD","IE00B3CCJ633.GBP","LU2023250843.SGD","LU1244550494.USD","LU0654597011.USD","IE00BGHQF417.EUR","LU0997586606.USD","LU1920063259.USD","ALB","LU2362541273.HKD","LU2106854487.HKD","BK4136","LU1803068623.USD","LU1244550221.USD","LU0053671581.USD","LU0048578792.EUR","OC","PFS","LU1244550577.SGD","LU0868494617.USD","LU1548497426.USD","LU1119994140.HKD","LU2041044095.USD","RKLB","KBR","LU2360106947.USD","LU2362540622.SGD","LU0612318385.USD","LU0997587240.USD","BK4548","BK4588","LU1720051108.HKD","LU1861214812.USD","LU2401740654.USD","LU2298321311.HKD","BK4123","BK4195","EVR","LU2242646235.USD","LU0612318971.USD","LU1989763427.SGD","BK4153","LU2023250504.SGD","LU2092937221.SGD","BK4585","CSTM","LU2242646821.SGD","SW","LU2380233275.USD"],"gpt_icon":1},{"id":"2522022206","title":"Provident Bank Announces $950,000 in NRTC Funding Awards to Ten New Jersey Non-Profit Organizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022206","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022206?lang=en_us&edition=fundamental","pubTime":"2025-03-25 20:00","pubTimestamp":1742904000,"startTime":"0","endTime":"0","summary":"Funds will be used to support revitalization plans for distressed neighborhoodsISELIN, N.J., March  25, 2025  (GLOBE NEWSWIRE) -- Provident Bank, a leading New Jersey-based financial institution, anno","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/25/3048657/0/en/Provident-Bank-Announces-950-000-in-NRTC-Funding-Awards-to-Ten-New-Jersey-Non-Profit-Organizations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK4211"],"gpt_icon":0},{"id":"2522021482","title":"Three Stocks Trading Below Estimated Value In March 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522021482","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522021482?lang=en_us&edition=fundamental","pubTime":"2025-03-25 19:07","pubTimestamp":1742900869,"startTime":"0","endTime":"0","summary":"As of March 2025, the U.S. stock market has seen a notable surge, with major indices like the S&P 500 and Nasdaq Composite making significant gains following positive developments around tariff policies. This environment presents an opportunity for investors to explore stocks that are trading below their estimated value, particularly as market conditions continue to evolve and investor sentiment improves.Top 10 Undervalued Stocks Based On Cash Flows In The United States. Overview: Ciena Corporation is a network technology company that offers hardware, software, and services to network operators across multiple regions worldwide, with a market cap of approximately $9.32 billion.Overview: Oracle Corporation provides products and services for enterprise information technology environments globally, with a market cap of approximately $426.89 billion.Oracle, trading at US$154.87, is significantly below its estimated fair v","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/three-stocks-trading-below-estimated-110749231.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0002270589.USD","LU1917777945.USD","LU0154245673.USD","IE00BLSP4452.SGD","LU1642822529.SGD","LU1863844749.USD","LU2242646235.USD","LU0997587240.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU0823421333.USD","LU0878866978.SGD","LU1069347547.HKD","LU0208291251.USD","LU0823421416.USD","BK4543","LU0130517989.USD","LU0965509010.AUD","PFS","LU0234570918.USD","LU1861217088.USD","LU2326559502.SGD","LU2380233275.USD","LU0550127509.SGD","BK4211","LU0476273544.USD","SW","LU1935042215.USD","LU0417517546.SGD","LU0433182093.SGD","CSTM","LU0068578508.USD","ALB","BK4109","CIEN","IE00B7SZLL34.SGD","LU0985489474.SGD","LU0348723411.USD","LU0654597011.USD","LU0612318971.USD","LU1064131342.USD","LU1035773651.USD","LU1074936037.SGD","IE0009356076.USD","BK4020","ORCL","BK4545","SCHW","KBR","LU0109392836.USD"],"gpt_icon":1},{"id":"2521406545","title":"HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2521406545","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521406545?lang=en_us&edition=fundamental","pubTime":"2025-03-21 18:00","pubTimestamp":1742551200,"startTime":"0","endTime":"0","summary":"— First and only EZH2 inhibitor approved by the NMPA—。— HUTCHMED’s fourth product, and its first approval in hematological malignancies—。“This approval represents a significant advancement in the management of this challenging disease. The majority of FL patients experience multiple relapses over their lifetime, posing substantial treatment difficulties and often leading to poor outcomes,” said Dr Junning Cao of Fudan University Cancer Center and the lead principal investigator of the bridging study. “TAZVERIK has demonstrated promising efficacy in patients harboring EZH2 mutation in clinical trials. We are eager to provide this transformational epigenetic therapy to patients in China who have long sought new effective treatment options.”TAZVERIK is a first-in-class methyltransferase inhibitor of EZH2 developed by Epizyme. It is approved by the US Food and Drug Administration  for the treatment of certain patients with R/R F","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hutchmed-announces-nmpa-conditional-approval-100000807.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","BK4195","BK4531","HCM","BK4211","OS","BK4097","PFS","BK4588"],"gpt_icon":0},{"id":"2520145379","title":"Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2520145379","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520145379?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472000,"startTime":"0","endTime":"0","summary":"Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma ForumSOUTH SAN FRANCISCO, Calif., March  20, 2025  (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc.(NASDAQ: CRVS), a ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/20/3046156/0/en/Corvus-Pharmaceuticals-Announces-Presentation-of-Additional-Data-from-the-Phase-1-1b-Clinical-Trial-of-Soquelitinib-for-Patients-with-T-Cell-Lymphoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4195","CRVS","BK4139","PFS","BK4568"],"gpt_icon":0},{"id":"2520941088","title":"Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2520941088","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520941088?lang=en_us&edition=fundamental","pubTime":"2025-03-19 15:14","pubTimestamp":1742368479,"startTime":"0","endTime":"0","summary":"HUTCHMED (China) (HKG:0013) and Innovent Biologics (HKG:1801) said their FRUSICA-2 Phase II/III study of fruquintinib in combination with sintilimab as a second line of treatment for advanced renal ce","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1583","BK1587","BK4195","LU2488822045.USD","BK1191","BK1588","PFS","LU1969619763.USD","00013","01801","BK1589","LU2328871848.SGD","BK4211"],"gpt_icon":0},{"id":"2520968934","title":"Press Release: CARsgen Announced 2024 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520968934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520968934?lang=en_us&edition=fundamental","pubTime":"2025-03-19 08:15","pubTimestamp":1742343300,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 18, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited , a company focused on developing innovative CAR T-cell therapies, announced its 2024 Annual Results.-- Zevor-cel was approved by China's National Medical Products. -- As of December 31, 2024, certification and filings for zevor-cel. completed in 23 provinces or cities, covering over 200 healthcare. institutes; CARsgen has received a total of 154 valid orders from its. enrollment has been completed, and the study has met its primary. published in Nature Medicine and at the 2024 ASCO Annual Meeting.-- The results of the IIT of an allogeneic BCMA-targeting CAR-T product. -- Introduced Zhuhai SB Xinchuang to accelerate allogeneic CAR-T development. Zevorcabtagene autoleucel  is an autologous fully human CAR T-cell product against B-cell maturation antigen . On February 23, 2024, zevor-cel was approved by China's NMPA for the treatment of adult patients with relapsed or refractory multiple myeloma  who have prog","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","BK4230","BK4017","BK4555","BK4022","BK4209","R","BK1574","BK4195","03160","TM","BK4211","BK1161","CAR","PFS","BK4099","02171","BK4585","PC","CDE","BK1585","BK1587","BK4588","BK4604"],"gpt_icon":1},{"id":"2520931134","title":"Press Release: OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931134","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931134?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:05","pubTimestamp":1742328300,"startTime":"0","endTime":"0","summary":"Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today. OmniAb, Inc.  today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program updates.\"2024 was a remarkable year featuring double-digit percentage growth in the number of both active partners and programs. Clinical-stage programs advanced well, and we launched new technologies and enhancements that strengthened our platform and expanded our reach,\" said Matt Foehr, Chief Executive Officer of OmniAb. \"We exceeded our internal goals for key metrics and continued to build momentum while optimizing the scalability of our business. We believe our commitment to innovation is a significant competitive advantage and creates exciting opportunities for future growth. We remain steadfast in our strategic direction and are excited about the prospects that lie ahead.\". Net loss for the fourth quarter of 2024 was $13.1 million, or $0.12 per share, compared with a net ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4195","BK4555","BK4121","TM","OS","PFS","GD","BK4211","BK4187","BK4516","BK4566","BK4097","BK4588","BK4232","BK4022","LU0170899867.USD","BK4604","OABI","BK4585","R","BK4550","03160"],"gpt_icon":0},{"id":"2520880146","title":"Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520880146","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520880146?lang=en_us&edition=fundamental","pubTime":"2025-03-18 04:05","pubTimestamp":1742241900,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc.   today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc.  to Sanofi S.A.  and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because the spin-off was accounted for as a reverse spin-off, for periods prior to the spin-off, the Company's financial statements are the historical financial statements of the Former Parent.Cash and Cash Equivalents. As of December31, 2024, Inhibrx had cash and cash equivalents of $152.6 million. Subsequent to year-end, the Company entered into the Oxford Loan Agreement and received gross proceeds of $100.0 million. As of February 28, 2025, Inhibrx had cash and cash equivalents of $230.5 million.Research and development expenses were $","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inhibrx-reports-fourth-quarter-fiscal-200500270.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inhibrx-reports-fourth-quarter-fiscal-200500270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["INBX","CRC","BK4213","BK4139","LU0456854461.SGD","PFS","LU0266512127.USD","BK4195","SOFR","BK4211"],"gpt_icon":0},{"id":"2520508082","title":"Top 3 Dividend Stocks To Consider For Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2520508082","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520508082?lang=en_us&edition=fundamental","pubTime":"2025-03-18 01:01","pubTimestamp":1742230898,"startTime":"0","endTime":"0","summary":"As the U.S. stock market grapples with volatility and mixed performances among major indices, investors are increasingly focused on strategies to mitigate risk and secure steady returns. In this climate, dividend stocks offer a compelling option by providing consistent income streams, making them an attractive consideration for those looking to bolster their portfolios amidst economic uncertainty.Overview: Dime Community Bancshares, Inc. is the holding company for Dime Community Bank, offering a range of commercial banking and financial services, with a market cap of approximately $1.22 billion.Operations: Dime Community Bancshares, Inc. generates its revenue primarily through its Community Banking segment, which accounts for $278 million.Dive into the specifics of Dime Community Bancshares here with our thorough dividend report.The valuation report we've compiled suggests that Dime Community Bancshares' current price could be quite moderate.Overview: Independent Bank Corp. is the bank","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-3-dividend-stocks-consider-170138137.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4009","RF","LU0130518102.USD","US3Y.BOND","DDS","US2Y.BOND","US30Y.BOND","DCOMP","DCOM","BK4149","BK4588","US6M.BOND","INDB","LU0130103400.USD","ISBA","US12M.BOND","LU0648000940.SGD","PFS","BK4220","BK4211","BK4585","IPG","US7Y.BOND","PLOW","LU0477156797.USD","US10Y.BOND","LU1201861165.SGD","BK4103","US5Y.BOND","BK4195"],"gpt_icon":0},{"id":"2520522383","title":"INAB: Introducing INB-600, A γδ T Cell Engager Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2520522383","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520522383?lang=en_us&edition=fundamental","pubTime":"2025-03-17 17:31","pubTimestamp":1742203860,"startTime":"0","endTime":"0","summary":"Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc.  reported 2024 financial and operational results on March 14th, 2025. Other corporate achievements since the third quarter report in mid-November include a stakeholder update on glioblastoma multiforme  and acute myeloid leukemia  efforts and presentations at multiple investor and scientific conferences.The most important information shared related to the INB-100 patients. Trial data was updated by about four months from early August 2024 to January 17th, 2025 and were presented at the Transplantation & Cellular Therapy  Meetings in February. All of the acute myeloid leukemia  patients across both original and expansion cohorts remain in complete remission , with a median follow-up of 20.1 months. All of the AML patients achieved one year of both progression free survival  and overall survival .General & administrative expenses were $12.6 million, falling 6.5% from $13.5 million. The decrease was pri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inab-introducing-inb-600-t-093100072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PFS","BK4161","CRS","IE0031619046.USD","BK4195","INB","LU2065731478.USD","OS","BK4097","IE00B7SZL793.SGD","BK4211","BK4006","IE00B66KJ199.SGD","BK4539","CR","IE00B19Z4B17.USD","BK4139","INAB"],"gpt_icon":0},{"id":"2519313450","title":"ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2519313450","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519313450?lang=en_us&edition=fundamental","pubTime":"2025-03-15 20:00","pubTimestamp":1742040000,"startTime":"0","endTime":"0","summary":"Final data analysis from Phase 3 MIRASOL trial after 30.5-month median follow-up demonstrated 32% reduction in risk of death with ELAHERE compared to chemotherapy in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer . Data presented in a late-breaking oral presentation at the Society of Gynecologic Oncology  Annual Meeting on Women's Cancer in Seattle. \"Ovarian cancer can be devastating, and when cancer cells stop responding to chemotherapy patients may feel hopeless about their journey. The data presented today reinforce the importance of ELAHERE as a transformative therapy for patients with limited options,\" said Svetlana Kobina, MD, PhD, vice president, oncology medical affairs, AbbVie. \"We remain steadfast in our commitment to bring forward innovative therapies that improve the lives of patients with difficult-to-treat cancers.\". In the United States, ovarian cancer is the leading cause of death from gynecological cancers.3 Each year, approximately 20,000 women","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/elahere-mirvetuximab-soravtansine-gynx-shows-120000918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1037948541.HKD","LU1989771016.USD","LU2237443895.HKD","LU1989772840.SGD","LU1934455277.USD","LU0738911758.USD","LU0795875086.SGD","LU1267930573.SGD","LU1430594728.SGD","BK4585","LU0545039389.USD","ADC","LU0985320562.USD","IE0002141913.USD","LU1983299246.USD","LU1037948897.HKD","LU2089984988.USD","LU2237443978.SGD","OS","ABBV","BK4581","LU0965508806.USD","LU0820561818.USD","BK4533","LU1496350502.SGD","LU1244550577.SGD","LU2237443465.HKD","IE00B4R5TH58.HKD","LU2112291526.USD","LU1244550494.USD","SG9999015952.SGD","SG9999015986.USD","LU1291159041.SGD","LU1732799900.SGD","PROC","BK4550","LU0320765646.SGD","PFS","LU0708994859.HKD","BK4080","LU0170899867.USD","LU0417517546.SGD","LU1244550221.USD","ORR","LU2089283258.USD","LU1162221912.USD","BK4195","IE00BVYPNV92.GBP","LU1003077747.HKD","IE00BJJMRZ35.SGD"],"gpt_icon":0},{"id":"2519705806","title":"Discover TSX Penny Stocks: Lion Copper and Gold Plus 2 More Hidden Gems","url":"https://stock-news.laohu8.com/highlight/detail?id=2519705806","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519705806?lang=en_us&edition=fundamental","pubTime":"2025-03-14 20:05","pubTimestamp":1741953915,"startTime":"0","endTime":"0","summary":"Amidst ongoing tariff tensions and political uncertainties, the Canadian market has shown resilience with the TSX posting a modest gain of 0.2% for the year despite broader global challenges. In such a cautious market atmosphere, identifying stocks with strong financial foundations becomes crucial for investors seeking potential growth opportunities. While 'penny stocks' might seem like an outdated term, they still offer significant potential when backed by solid fundamentals. Below, we explore three penny stocks that exemplify financial strength and growth potential in today's market landscape.Overview: Lion Copper and Gold Corp. is a mineral exploration company focused on acquiring, exploring, and developing copper projects in the United States, with a market cap of CA$36.99 million.Overview: Avino Silver & Gold Mines Ltd. is involved in acquiring, exploring, and developing mineral properties in Canada with a market cap of CA$348.36 million.Operations: Avino Silver & Gold Mines Ltd. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/discover-tsx-penny-stocks-lion-120515182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1791807156.HKD","LU1861217088.USD","LU0106831901.USD","BK4166","PFS","BK4211","LU1861220207.SGD","LU2360107671.USD","LU1668664300.SGD","DFS","BK4188","BK4585","ASM","BK4588","BK4195"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PFS\",params:#limit:5,,,undefined,":[{"date":"2025-05-16","symbol":"PFS","amount":0.24,"announcedDate":"2025-04-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-16","defaultRemindTime":1747402200000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-30","payableDate":"2025-05-16","currency":"USD","dateTimestamp":1747368000000,"payDate":"2025-05-30"},{"date":"2025-04-24","symbol":"PFS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":0.47,"defaultRemindTime":1745524800000,"name":null,"time":"Post Market","dateTimestamp":1745467200000,"actualEps":null},{"date":"2025-02-14","symbol":"PFS","amount":0.24,"announcedDate":"2025-01-28","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-14","defaultRemindTime":1739543400000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-28","payableDate":"2025-02-14","currency":"USD","dateTimestamp":1739509200000,"payDate":"2025-02-28"},{"market":"US","date":"2025-01-28","symbol":"PFS","fiscalQuarterEnding":"2024/12","expectedEps":0.5,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.37},{"date":"2024-11-15","symbol":"PFS","amount":0.24,"announcedDate":"2024-10-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-15","defaultRemindTime":1731681000000,"name":"Provident Financial Services Inc","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-29","payableDate":"2024-11-15","currency":"USD","dateTimestamp":1731646800000,"payDate":"2024-11-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PFS\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-13","recordDate":"2015-05-15","paymentDate":"2015-05-29","value":0.16,"currency":"USD"},{"executeDate":"2015-08-12","recordDate":"2015-08-14","paymentDate":"2015-08-28","value":0.16,"currency":"USD"},{"executeDate":"2015-11-10","recordDate":"2015-11-13","paymentDate":"2015-11-27","value":0.17,"currency":"USD"},{"executeDate":"2016-02-10","recordDate":"2016-02-12","paymentDate":"2016-02-26","value":0.17,"currency":"USD"},{"executeDate":"2016-05-11","recordDate":"2016-05-13","paymentDate":"2016-05-31","value":0.18,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PFS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.8333,"hold":0.1667,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1734148800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PFS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PFS","date":"2025-04-28","current":14.654875,"percent":0.743902,"low":6.410614,"twenty":8.695921,"median":10.357421,"eighty":16.512412,"high":33.980228,"avg":12.887623,"sd":6.399504,"marketCap":2161169063},"quantilePoints":[{"date":"2020-05-01","current":9.095426,"twenty":14.024503,"median":17.544322,"eighty":19.049774,"marketCap":879291222},{"date":"2020-05-08","current":8.942283,"twenty":13.850794,"median":17.544322,"eighty":19.049774,"marketCap":864486279},{"date":"2020-05-15","current":7.690497,"twenty":13.45386,"median":17.544322,"eighty":19.049774,"marketCap":743471074},{"date":"2020-05-22","current":8.31639,"twenty":13.355525,"median":17.544322,"eighty":19.049774,"marketCap":803978677},{"date":"2020-05-29","current":8.675946,"twenty":13.325105,"median":17.544322,"eighty":19.049774,"marketCap":838738363},{"date":"2020-06-05","current":10.060901,"twenty":13.301991,"median":17.544322,"eighty":19.049774,"marketCap":972627526},{"date":"2020-06-12","current":8.802456,"twenty":13.236148,"median":17.54157,"eighty":19.049774,"marketCap":850968623},{"date":"2020-06-19","current":8.702579,"twenty":13.220184,"median":17.524378,"eighty":19.049774,"marketCap":841313155},{"date":"2020-06-26","current":8.695921,"twenty":13.193521,"median":17.503783,"eighty":19.049774,"marketCap":840669457},{"date":"2020-07-02","current":9.022184,"twenty":13.181803,"median":17.497343,"eighty":19.049774,"marketCap":872210654},{"date":"2020-07-10","current":8.9556,"twenty":13.133798,"median":17.475453,"eighty":19.049774,"marketCap":865773675},{"date":"2020-07-17","current":9.375082,"twenty":13.113766,"median":17.448564,"eighty":19.049774,"marketCap":906326643},{"date":"2020-07-24","current":9.601469,"twenty":13.098537,"median":17.431245,"eighty":19.049774,"marketCap":928212371},{"date":"2020-07-31","current":10.146984,"twenty":13.0648,"median":17.422118,"eighty":19.049774,"marketCap":878647633},{"date":"2020-08-07","current":10.689643,"twenty":13.048711,"median":17.403942,"eighty":19.049774,"marketCap":925637580},{"date":"2020-08-14","current":10.527035,"twenty":13.031177,"median":17.388517,"eighty":19.049774,"marketCap":911556975},{"date":"2020-08-21","current":9.599052,"twenty":13.008395,"median":17.362339,"eighty":19.049774,"marketCap":831201106},{"date":"2020-08-28","current":9.947973,"twenty":12.988694,"median":17.334295,"eighty":19.049774,"marketCap":861414913},{"date":"2020-09-04","current":10.155841,"twenty":12.944965,"median":17.31872,"eighty":19.049774,"marketCap":879414627},{"date":"2020-09-11","current":9.509966,"twenty":12.926046,"median":17.247931,"eighty":19.049774,"marketCap":823486942},{"date":"2020-09-18","current":9.539661,"twenty":12.903594,"median":17.204455,"eighty":19.049774,"marketCap":826058330},{"date":"2020-09-25","current":8.916057,"twenty":12.85637,"median":17.165483,"eighty":19.049774,"marketCap":772059186},{"date":"2020-10-02","current":9.457999,"twenty":12.836682,"median":17.1464,"eighty":19.049774,"marketCap":818987014},{"date":"2020-10-09","current":9.777225,"twenty":12.825762,"median":17.106994,"eighty":19.030829,"marketCap":846629433},{"date":"2020-10-16","current":9.658443,"twenty":12.807943,"median":17.057235,"eighty":18.996004,"marketCap":836343881},{"date":"2020-10-23","current":10.222656,"twenty":12.774984,"median":17.027417,"eighty":18.941136,"marketCap":885200250},{"date":"2020-10-30","current":10.595048,"twenty":12.75677,"median":16.971439,"eighty":18.91343,"marketCap":872343311},{"date":"2020-11-06","current":10.696549,"twenty":12.723452,"median":16.947615,"eighty":18.891695,"marketCap":880700321},{"date":"2020-11-13","current":13.674488,"twenty":12.723452,"median":16.898923,"eighty":18.890505,"marketCap":1125888942},{"date":"2020-11-20","current":14.639195,"twenty":12.723452,"median":16.877422,"eighty":18.890505,"marketCap":1205318094},{"date":"2020-11-27","current":15.191794,"twenty":12.723452,"median":16.856678,"eighty":18.890505,"marketCap":1250816345},{"date":"2020-12-04","current":16.053474,"twenty":12.723452,"median":16.820466,"eighty":18.876273,"marketCap":1321762772},{"date":"2020-12-11","current":16.072206,"twenty":12.723452,"median":16.79439,"eighty":18.876273,"marketCap":1323305085},{"date":"2020-12-18","current":16.222063,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1335643594},{"date":"2020-12-24","current":16.718466,"twenty":12.723452,"median":16.730308,"eighty":18.876273,"marketCap":1376514905},{"date":"2020-12-31","current":16.821493,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1384997630},{"date":"2021-01-08","current":18.095281,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1489874956},{"date":"2021-01-15","current":17.992254,"twenty":12.723452,"median":16.744122,"eighty":18.876273,"marketCap":1481392232},{"date":"2021-01-22","current":18.142111,"twenty":12.723452,"median":16.774835,"eighty":18.876273,"marketCap":1493730740},{"date":"2021-01-29","current":14.720538,"twenty":12.723452,"median":16.78893,"eighty":18.876273,"marketCap":1427170886},{"date":"2021-02-05","current":15.094115,"twenty":12.723452,"median":16.757917,"eighty":18.876273,"marketCap":1463389586},{"date":"2021-02-12","current":15.571023,"twenty":12.723452,"median":16.755695,"eighty":18.876273,"marketCap":1509626224},{"date":"2021-02-19","current":15.626662,"twenty":12.723452,"median":16.724895,"eighty":18.876273,"marketCap":1515020498},{"date":"2021-02-26","current":16.079724,"twenty":12.723452,"median":16.714233,"eighty":18.876273,"marketCap":1558945304},{"date":"2021-03-05","current":17.794179,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1725163471},{"date":"2021-03-12","current":18.789768,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1821686827},{"date":"2021-03-19","current":18.215526,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1766013442},{"date":"2021-03-26","current":18.002063,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1745317972},{"date":"2021-04-01","current":17.749069,"twenty":12.723452,"median":16.674486,"eighty":18.876273,"marketCap":1720790008},{"date":"2021-04-09","current":18.24715,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1769079438},{"date":"2021-04-16","current":18.405271,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1784409415},{"date":"2021-04-23","current":18.674076,"twenty":12.721872,"median":16.671636,"eighty":18.877325,"marketCap":1810470378},{"date":"2021-04-30","current":14.042944,"twenty":12.721872,"median":16.669814,"eighty":18.884491,"marketCap":1833713567},{"date":"2021-05-07","current":15.049841,"twenty":12.721872,"median":16.625436,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-05-14","current":15.169001,"twenty":12.721872,"median":16.591954,"eighty":18.884491,"marketCap":1980752967},{"date":"2021-05-21","current":15.133253,"twenty":12.721872,"median":16.545238,"eighty":18.884491,"marketCap":1976085049},{"date":"2021-05-28","current":15.049841,"twenty":12.721872,"median":16.529666,"eighty":18.884491,"marketCap":1965193242},{"date":"2021-06-04","current":15.043883,"twenty":12.721872,"median":16.506308,"eighty":18.884491,"marketCap":1964415256},{"date":"2021-06-11","current":14.722153,"twenty":12.721872,"median":16.44402,"eighty":18.884491,"marketCap":1922403999},{"date":"2021-06-18","current":13.679507,"twenty":12.721872,"median":16.40509,"eighty":18.884491,"marketCap":1786256407},{"date":"2021-06-25","current":14.227641,"twenty":12.721872,"median":16.3245,"eighty":18.884491,"marketCap":1857831141},{"date":"2021-07-02","current":13.500768,"twenty":12.721872,"median":16.302281,"eighty":18.884491,"marketCap":1762916819},{"date":"2021-07-09","current":13.244575,"twenty":12.721872,"median":16.261288,"eighty":18.884491,"marketCap":1729463411},{"date":"2021-07-16","current":12.976467,"twenty":12.721872,"median":16.250162,"eighty":18.884491,"marketCap":1694454030},{"date":"2021-07-23","current":12.55345,"twenty":12.69964,"median":16.222063,"eighty":18.884491,"marketCap":1639217007},{"date":"2021-07-30","current":10.433885,"twenty":12.684833,"median":16.184117,"eighty":18.884491,"marketCap":1680450278},{"date":"2021-08-06","current":10.849309,"twenty":12.675728,"median":16.148152,"eighty":18.884491,"marketCap":1747357095},{"date":"2021-08-13","current":10.552042,"twenty":12.660863,"median":16.109223,"eighty":18.884491,"marketCap":1699480276},{"date":"2021-08-20","current":10.381313,"twenty":12.614911,"median":16.079724,"eighty":18.884491,"marketCap":1671983067},{"date":"2021-08-27","current":10.571012,"twenty":12.560516,"median":16.051403,"eighty":18.884491,"marketCap":1702535521},{"date":"2021-09-03","current":10.362343,"twenty":12.528973,"median":16.012247,"eighty":18.884491,"marketCap":1668927821},{"date":"2021-09-10","current":10.43348,"twenty":12.478039,"median":15.976834,"eighty":18.884491,"marketCap":1680384992},{"date":"2021-09-17","current":10.542557,"twenty":12.463634,"median":15.915973,"eighty":18.884491,"marketCap":1697952653},{"date":"2021-09-24","current":10.841334,"twenty":12.367008,"median":15.852207,"eighty":18.884491,"marketCap":1746072768},{"date":"2021-10-01","current":11.315583,"twenty":12.317066,"median":15.827979,"eighty":18.884491,"marketCap":1822453904},{"date":"2021-10-08","current":11.718695,"twenty":12.271397,"median":15.788905,"eighty":18.884491,"marketCap":1887377870},{"date":"2021-10-15","current":11.713953,"twenty":12.250326,"median":15.716295,"eighty":18.884491,"marketCap":1886614059},{"date":"2021-10-22","current":11.808802,"twenty":12.188782,"median":15.680935,"eighty":18.884491,"marketCap":1901890286},{"date":"2021-10-29","current":11.169949,"twenty":12.144658,"median":15.649322,"eighty":18.884491,"marketCap":1912127768},{"date":"2021-11-05","current":11.584988,"twenty":12.022084,"median":15.636232,"eighty":18.884491,"marketCap":1983176134},{"date":"2021-11-12","current":11.413559,"twenty":11.87183,"median":15.555472,"eighty":18.877325,"marketCap":1953830070},{"date":"2021-11-19","current":11.06619,"twenty":11.803248,"median":15.475641,"eighty":18.822017,"marketCap":1894365677},{"date":"2021-11-26","current":10.935362,"twenty":11.752841,"median":15.361209,"eighty":18.799671,"marketCap":1871969996},{"date":"2021-12-03","current":10.660174,"twenty":11.700674,"median":15.25837,"eighty":18.766081,"marketCap":1824861840},{"date":"2021-12-10","current":10.64664,"twenty":11.597269,"median":15.189807,"eighty":18.713257,"marketCap":1822545046},{"date":"2021-12-17","current":10.745888,"twenty":11.515514,"median":15.166494,"eighty":18.654746,"marketCap":1839534872},{"date":"2021-12-23","current":10.957919,"twenty":11.442431,"median":15.126556,"eighty":18.639247,"marketCap":1875831320},{"date":"2021-12-31","current":10.92634,"twenty":11.368446,"median":15.085589,"eighty":18.621596,"marketCap":1870425466},{"date":"2022-01-07","current":11.738372,"twenty":11.326022,"median":15.058778,"eighty":18.579091,"marketCap":2009433139},{"date":"2022-01-14","current":11.729349,"twenty":11.326022,"median":15.040904,"eighty":18.531427,"marketCap":2007888610},{"date":"2022-01-21","current":10.863182,"twenty":11.299875,"median":15.028989,"eighty":18.489553,"marketCap":1859613758},{"date":"2022-01-28","current":11.023748,"twenty":11.261979,"median":15.001772,"eighty":18.453467,"marketCap":1851118845},{"date":"2022-02-04","current":11.088134,"twenty":11.181448,"median":14.930112,"eighty":18.423167,"marketCap":1861930553},{"date":"2022-02-11","current":10.92717,"twenty":11.115728,"median":14.912327,"eighty":18.41438,"marketCap":1834901283},{"date":"2022-02-18","current":10.92717,"twenty":11.065654,"median":14.87528,"eighty":18.386528,"marketCap":1834901283},{"date":"2022-02-25","current":10.732094,"twenty":11.023748,"median":14.820597,"eighty":18.371521,"marketCap":1802143926},{"date":"2022-03-04","current":10.629654,"twenty":11.007105,"median":14.772796,"eighty":18.349914,"marketCap":1784942161},{"date":"2022-03-11","current":10.652348,"twenty":10.957288,"median":14.734826,"eighty":18.315942,"marketCap":1788752883},{"date":"2022-03-18","current":10.806664,"twenty":10.92634,"median":14.709739,"eighty":18.308123,"marketCap":1814665792},{"date":"2022-03-25","current":10.720428,"twenty":10.866543,"median":14.669048,"eighty":18.291682,"marketCap":1800185049},{"date":"2022-04-01","current":10.629654,"twenty":10.847714,"median":14.635382,"eighty":18.253335,"marketCap":1784942161},{"date":"2022-04-08","current":10.053238,"twenty":10.819838,"median":14.583758,"eighty":18.229989,"marketCap":1688149823},{"date":"2022-04-14","current":10.071393,"twenty":10.805336,"median":14.512906,"eighty":18.210171,"marketCap":1691198401},{"date":"2022-04-22","current":10.171245,"twenty":10.764,"median":14.497563,"eighty":18.192392,"marketCap":1707965577},{"date":"2022-04-29","current":10.150722,"twenty":10.733654,"median":14.451873,"eighty":18.177577,"marketCap":1657856535},{"date":"2022-05-06","current":10.297502,"twenty":10.713769,"median":14.383195,"eighty":18.14275,"marketCap":1681829155},{"date":"2022-05-13","current":9.954658,"twenty":10.67461,"median":14.304676,"eighty":18.117189,"marketCap":1625834598},{"date":"2022-05-20","current":10.078233,"twenty":10.650249,"median":14.249341,"eighty":18.096905,"marketCap":1646017372},{"date":"2022-05-27","current":10.572534,"twenty":10.629654,"median":14.193648,"eighty":18.064002,"marketCap":1726748469},{"date":"2022-06-03","current":10.412344,"twenty":10.620376,"median":14.117725,"eighty":18.057139,"marketCap":1700585614},{"date":"2022-06-10","current":10.000427,"twenty":10.605236,"median":13.994542,"eighty":18.016495,"marketCap":1633309699},{"date":"2022-06-17","current":9.92262,"twenty":10.570637,"median":13.872371,"eighty":17.998745,"marketCap":1620602026},{"date":"2022-06-24","current":10.165194,"twenty":10.552314,"median":13.685465,"eighty":17.991294,"marketCap":1660220065},{"date":"2022-07-01","current":10.513034,"twenty":10.530137,"median":13.611721,"eighty":17.968495,"marketCap":1717030837},{"date":"2022-07-08","current":10.31623,"twenty":10.524934,"median":13.456373,"eighty":17.95339,"marketCap":1684887900},{"date":"2022-07-15","current":10.288769,"twenty":10.512341,"median":13.392091,"eighty":17.910649,"marketCap":1680402839},{"date":"2022-07-22","current":10.613725,"twenty":10.505887,"median":13.327225,"eighty":17.849237,"marketCap":1733476061},{"date":"2022-07-29","current":11.467199,"twenty":10.505887,"median":13.302306,"eighty":17.813962,"marketCap":1809111112},{"date":"2022-08-05","current":11.377758,"twenty":10.505887,"median":13.239282,"eighty":17.786291,"marketCap":1795000639},{"date":"2022-08-12","current":11.739288,"twenty":10.505887,"median":13.221695,"eighty":17.762714,"marketCap":1852037025},{"date":"2022-08-19","current":11.748717,"twenty":10.505887,"median":13.209959,"eighty":17.748875,"marketCap":1853524605},{"date":"2022-08-26","current":11.296118,"twenty":10.505887,"median":13.188531,"eighty":17.733901,"marketCap":1782120768},{"date":"2022-09-02","current":10.848234,"twenty":10.505887,"median":13.150076,"eighty":17.684237,"marketCap":1711460720},{"date":"2022-09-09","current":10.928381,"twenty":10.505887,"median":13.130958,"eighty":17.66138,"marketCap":1724105150},{"date":"2022-09-16","current":11.036817,"twenty":10.505887,"median":13.113536,"eighty":17.644475,"marketCap":1741212319},{"date":"2022-09-23","current":10.980242,"twenty":10.505887,"median":13.081395,"eighty":17.623016,"marketCap":1732286840},{"date":"2022-09-30","current":9.193418,"twenty":10.478391,"median":13.065324,"eighty":17.59628,"marketCap":1450390441},{"date":"2022-10-07","current":9.075554,"twenty":10.469523,"median":13.052449,"eighty":17.561143,"marketCap":1431795692},{"date":"2022-10-14","current":9.580013,"twenty":10.437974,"median":13.034632,"eighty":17.546569,"marketCap":1511381219},{"date":"2022-10-21","current":9.716736,"twenty":10.425892,"median":13.011756,"eighty":17.514492,"marketCap":1532951128},{"date":"2022-10-28","current":10.271339,"twenty":10.389888,"median":12.992653,"eighty":17.479985,"marketCap":1683636796},{"date":"2022-11-04","current":10.266754,"twenty":10.377223,"median":12.955005,"eighty":17.444428,"marketCap":1682885173},{"date":"2022-11-11","current":10.291061,"twenty":10.357421,"median":12.934931,"eighty":17.408903,"marketCap":1686869566},{"date":"2022-11-18","current":10.064186,"twenty":10.320716,"median":12.924436,"eighty":17.359105,"marketCap":1649681083},{"date":"2022-11-25","current":10.272911,"twenty":10.310098,"median":12.883192,"eighty":17.323674,"marketCap":1683894487},{"date":"2022-12-02","current":10.204848,"twenty":10.293993,"median":12.857307,"eighty":17.216387,"marketCap":1672737942},{"date":"2022-12-09","current":9.973436,"twenty":10.282719,"median":12.842174,"eighty":17.162345,"marketCap":1634805690},{"date":"2022-12-16","current":9.360873,"twenty":10.269156,"median":12.829982,"eighty":17.036971,"marketCap":1534396787},{"date":"2022-12-23","current":9.719335,"twenty":10.253097,"median":12.811402,"eighty":16.964208,"marketCap":1593154590},{"date":"2022-12-30","current":9.69211,"twenty":10.230259,"median":12.79325,"eighty":16.866633,"marketCap":1588691972},{"date":"2023-01-06","current":9.896298,"twenty":10.216454,"median":12.770698,"eighty":16.761899,"marketCap":1622161606},{"date":"2023-01-13","current":10.150398,"twenty":10.193425,"median":12.743914,"eighty":16.690368,"marketCap":1663812707},{"date":"2023-01-20","current":10.213923,"twenty":10.187062,"median":12.725033,"eighty":16.523587,"marketCap":1674225482},{"date":"2023-01-27","current":9.790009,"twenty":10.173843,"median":12.690346,"eighty":16.324736,"marketCap":1719595430},{"date":"2023-02-03","current":10.396723,"twenty":10.16752,"median":12.677807,"eighty":16.256402,"marketCap":1826163591},{"date":"2023-02-10","current":10.238158,"twenty":10.16752,"median":12.667312,"eighty":16.23143,"marketCap":1798311961},{"date":"2023-02-17","current":10.259586,"twenty":10.15802,"median":12.637027,"eighty":16.127135,"marketCap":1802075695},{"date":"2023-02-24","current":10.011024,"twenty":10.149032,"median":12.580612,"eighty":16.062409,"marketCap":1758416384},{"date":"2023-03-03","current":9.946656,"twenty":10.12732,"median":12.54984,"eighty":16.029311,"marketCap":1747110222},{"date":"2023-03-10","current":8.806492,"twenty":10.110262,"median":12.491259,"eighty":15.99002,"marketCap":1546842669},{"date":"2023-03-17","current":8.551231,"twenty":10.087476,"median":12.467781,"eighty":15.924154,"marketCap":1502006690},{"date":"2023-03-24","current":8.308734,"twenty":10.075497,"median":12.378703,"eighty":15.861307,"marketCap":1459412470},{"date":"2023-03-31","current":8.159832,"twenty":10.060803,"median":12.352386,"eighty":15.839714,"marketCap":1433258125},{"date":"2023-04-06","current":7.704617,"twenty":10.04356,"median":12.287536,"eighty":15.796939,"marketCap":1353300555},{"date":"2023-04-14","current":7.832247,"twenty":10.027135,"median":12.261119,"eighty":15.730693,"marketCap":1375718565},{"date":"2023-04-21","current":7.74716,"twenty":10.017452,"median":12.211348,"eighty":15.694,"marketCap":1360773225},{"date":"2023-04-28","current":7.593207,"twenty":9.999766,"median":12.160062,"eighty":15.664957,"marketCap":1307717267},{"date":"2023-05-05","current":6.573548,"twenty":9.989771,"median":12.09154,"eighty":15.642667,"marketCap":1132109520},{"date":"2023-05-12","current":6.495446,"twenty":9.971621,"median":11.987273,"eighty":15.600987,"marketCap":1118658713},{"date":"2023-05-19","current":7.029498,"twenty":9.961387,"median":11.888242,"eighty":15.530275,"marketCap":1210634281},{"date":"2023-05-26","current":7.046909,"twenty":9.952827,"median":11.808802,"eighty":15.39865,"marketCap":1213632756},{"date":"2023-06-02","current":7.116551,"twenty":9.943684,"median":11.780347,"eighty":15.324881,"marketCap":1225626656},{"date":"2023-06-09","current":7.90873,"twenty":9.929925,"median":11.738372,"eighty":15.203096,"marketCap":1362057268},{"date":"2023-06-16","current":7.934846,"twenty":9.905841,"median":11.713953,"eighty":15.174007,"marketCap":1366554981},{"date":"2023-06-23","current":7.221014,"twenty":9.886325,"median":11.649929,"eighty":15.134319,"marketCap":1243617506},{"date":"2023-06-30","current":7.260188,"twenty":9.866996,"median":11.584988,"eighty":15.109317,"marketCap":1250364075},{"date":"2023-07-07","current":6.946798,"twenty":9.848756,"median":11.548897,"eighty":15.068412,"marketCap":1196391525},{"date":"2023-07-14","current":7.499583,"twenty":9.820363,"median":11.505283,"eighty":15.049841,"marketCap":1291593106},{"date":"2023-07-21","current":8.108951,"twenty":9.78572,"median":11.467199,"eighty":15.032889,"marketCap":1396539731},{"date":"2023-07-28","current":8.682159,"twenty":9.742349,"median":11.428126,"eighty":15.003286,"marketCap":1432521431},{"date":"2023-08-04","current":8.409258,"twenty":9.731294,"median":11.387173,"eighty":14.9415,"marketCap":1387493907},{"date":"2023-08-11","current":8.120111,"twenty":9.718285,"median":11.354912,"eighty":14.916422,"marketCap":1339785831},{"date":"2023-08-18","current":7.624539,"twenty":9.704927,"median":11.300777,"eighty":14.879018,"marketCap":1258018387},{"date":"2023-08-25","current":7.506329,"twenty":9.663774,"median":11.282731,"eighty":14.826043,"marketCap":1238514226},{"date":"2023-09-01","current":7.492689,"twenty":9.624389,"median":11.244446,"eighty":14.781733,"marketCap":1236263745},{"date":"2023-09-08","current":7.310828,"twenty":9.599052,"median":11.197237,"eighty":14.751943,"marketCap":1206257344},{"date":"2023-09-15","current":7.388119,"twenty":9.572255,"median":11.168825,"eighty":14.716388,"marketCap":1219010065},{"date":"2023-09-22","current":6.997117,"twenty":9.538302,"median":11.11225,"eighty":14.678775,"marketCap":1154496301},{"date":"2023-09-29","current":6.951652,"twenty":9.501581,"median":11.06619,"eighty":14.644899,"marketCap":1146994701},{"date":"2023-10-06","current":6.951652,"twenty":9.471361,"median":11.046743,"eighty":14.595078,"marketCap":1146994701},{"date":"2023-10-13","current":6.792523,"twenty":9.431033,"median":11.012054,"eighty":14.515019,"marketCap":1120739099},{"date":"2023-10-20","current":6.542463,"twenty":9.372419,"median":10.980475,"eighty":14.499896,"marketCap":1079480297},{"date":"2023-10-27","current":7.170747,"twenty":9.358917,"median":10.957919,"eighty":14.471655,"marketCap":1076479657},{"date":"2023-11-03","current":7.537213,"twenty":9.227549,"median":10.936586,"eighty":14.399708,"marketCap":1131493992},{"date":"2023-11-10","current":7.179977,"twenty":9.151165,"median":10.92634,"eighty":14.31961,"marketCap":1077865333},{"date":"2023-11-17","current":7.734589,"twenty":9.108811,"median":10.883634,"eighty":14.267749,"marketCap":1161124242},{"date":"2023-11-24","current":7.594687,"twenty":9.078197,"median":10.857,"eighty":14.214839,"marketCap":1140121995},{"date":"2023-12-01","current":7.60468,"twenty":8.976162,"median":10.840069,"eighty":14.143037,"marketCap":1141622155},{"date":"2023-12-08","current":8.214253,"twenty":8.928966,"median":10.82028,"eighty":14.03685,"marketCap":1233131947},{"date":"2023-12-15","current":9.103631,"twenty":8.896863,"median":10.805953,"eighty":13.930523,"marketCap":1366646233},{"date":"2023-12-22","current":9.083645,"twenty":8.896863,"median":10.78687,"eighty":13.759594,"marketCap":1363645912},{"date":"2023-12-29","current":9.223547,"twenty":8.892939,"median":10.761277,"eighty":13.668342,"marketCap":1384648159},{"date":"2024-01-05","current":8.743883,"twenty":8.862382,"median":10.745888,"eighty":13.56351,"marketCap":1312640455},{"date":"2024-01-12","current":8.583995,"twenty":8.806492,"median":10.720428,"eighty":13.408162,"marketCap":1288637886},{"date":"2024-01-19","current":8.309187,"twenty":8.772881,"median":10.697142,"eighty":13.342249,"marketCap":1247383472},{"date":"2024-01-26","current":8.828824,"twenty":8.752732,"median":10.656886,"eighty":13.316627,"marketCap":1325391819},{"date":"2024-02-02","current":9.490046,"twenty":8.752732,"median":10.64215,"eighty":13.30073,"marketCap":1218502920},{"date":"2024-02-09","current":8.830529,"twenty":8.752732,"median":10.629654,"eighty":13.236743,"marketCap":1133822213},{"date":"2024-02-16","current":9.326626,"twenty":8.752732,"median":10.620577,"eighty":13.221244,"marketCap":1197520090},{"date":"2024-02-23","current":8.865547,"twenty":8.752732,"median":10.61055,"eighty":13.209959,"marketCap":1138318534},{"date":"2024-03-01","current":8.801346,"twenty":8.74965,"median":10.589265,"eighty":13.19135,"marketCap":1130075279},{"date":"2024-03-08","current":8.986315,"twenty":8.743883,"median":10.567288,"eighty":13.154274,"marketCap":1153824926},{"date":"2024-03-15","current":8.329352,"twenty":8.723902,"median":10.538449,"eighty":13.128485,"marketCap":1069472190},{"date":"2024-03-22","current":8.96157,"twenty":8.698898,"median":10.5269,"eighty":13.112465,"marketCap":1150647615},{"date":"2024-03-28","current":8.466976,"twenty":8.693607,"median":10.517516,"eighty":13.098537,"marketCap":1087142753},{"date":"2024-04-05","current":8.466976,"twenty":8.653336,"median":10.488954,"eighty":13.065324,"marketCap":1087142753},{"date":"2024-04-12","current":7.990046,"twenty":8.61897,"median":10.476162,"eighty":13.052449,"marketCap":1025905922},{"date":"2024-04-19","current":8.671317,"twenty":8.578848,"median":10.466677,"eighty":13.034632,"marketCap":1040072426},{"date":"2024-04-26","current":9.585747,"twenty":8.579877,"median":10.437517,"eighty":13.020302,"marketCap":1149752791},{"date":"2024-05-03","current":9.605463,"twenty":8.579877,"median":10.431596,"eighty":12.999364,"marketCap":1152117669},{"date":"2024-05-10","current":10.091416,"twenty":8.579877,"median":10.40199,"eighty":12.962642,"marketCap":1210404831},{"date":"2024-05-17","current":10.167149,"twenty":8.579877,"median":10.387579,"eighty":12.944965,"marketCap":1219488545},{"date":"2024-05-24","current":9.554974,"twenty":8.579877,"median":10.368229,"eighty":12.926046,"marketCap":1146061860},{"date":"2024-05-31","current":9.031155,"twenty":8.579877,"median":10.357421,"eighty":12.90972,"marketCap":1083232842},{"date":"2024-06-07","current":8.639868,"twenty":8.579877,"median":10.32448,"eighty":12.882781,"marketCap":1036300321},{"date":"2024-06-14","current":8.494713,"twenty":8.57296,"median":10.31623,"eighty":12.877209,"marketCap":1018889870},{"date":"2024-06-21","current":8.53258,"twenty":8.56142,"median":10.296725,"eighty":12.877995,"marketCap":1023431727},{"date":"2024-06-28","current":8.608313,"twenty":8.557426,"median":10.288769,"eighty":12.87427,"marketCap":1032515441},{"date":"2024-07-05","current":9.17631,"twenty":8.557426,"median":10.28051,"eighty":12.856219,"marketCap":1100643293},{"date":"2024-07-12","current":10.066172,"twenty":8.557426,"median":10.267199,"eighty":12.83418,"marketCap":1207376927},{"date":"2024-07-15","current":10.141905,"twenty":8.557426,"median":10.266754,"eighty":12.829982,"marketCap":1216460640},{"date":"2024-08-02","current":30.236968,"twenty":8.550513,"median":10.244363,"eighty":12.813454,"marketCap":2311767376},{"date":"2024-08-09","current":28.994819,"twenty":8.550513,"median":10.244363,"eighty":12.829982,"marketCap":2216798880},{"date":"2024-08-16","current":30.839915,"twenty":8.550513,"median":10.244363,"eighty":12.847792,"marketCap":2357865738},{"date":"2024-08-23","current":30.942317,"twenty":8.550513,"median":10.244363,"eighty":12.868391,"marketCap":2365694844},{"date":"2024-08-30","current":32.290603,"twenty":8.550513,"median":10.244363,"eighty":12.926535,"marketCap":2468778073},{"date":"2024-09-06","current":31.86393,"twenty":8.550513,"median":10.244363,"eighty":12.95098,"marketCap":2436156798},{"date":"2024-09-13","current":30.379109,"twenty":8.550513,"median":10.244363,"eighty":12.978743,"marketCap":2322634762},{"date":"2024-09-20","current":33.178083,"twenty":8.550513,"median":10.244363,"eighty":12.986356,"marketCap":2536630324},{"date":"2024-09-27","current":30.92525,"twenty":8.550513,"median":10.244363,"eighty":13.030742,"marketCap":2364389993},{"date":"2024-10-04","current":30.174306,"twenty":8.550513,"median":10.244363,"eighty":13.065239,"marketCap":2306976550},{"date":"2024-10-11","current":30.874049,"twenty":8.550513,"median":10.244363,"eighty":13.110396,"marketCap":2360475440},{"date":"2024-10-18","current":33.980228,"twenty":8.550513,"median":10.244363,"eighty":13.135891,"marketCap":2597958321},{"date":"2024-10-25","current":32.512473,"twenty":8.550513,"median":10.244363,"eighty":13.18261,"marketCap":2485741135},{"date":"2024-10-31","current":26.328623,"twenty":8.550513,"median":10.244363,"eighty":13.18261,"marketCap":2483131433},{"date":"2024-11-08","current":29.275547,"twenty":8.550153,"median":10.241149,"eighty":13.17502,"marketCap":2761064694},{"date":"2024-11-15","current":29.635999,"twenty":8.550153,"median":10.241149,"eighty":13.220364,"marketCap":2795059964},{"date":"2024-11-22","current":28.847366,"twenty":8.550153,"median":10.241149,"eighty":13.27236,"marketCap":2720681617},{"date":"2024-11-29","current":29.220929,"twenty":8.550153,"median":10.241149,"eighty":13.402862,"marketCap":2755913466},{"date":"2024-12-06","current":28.529146,"twenty":8.550153,"median":10.241149,"eighty":13.662197,"marketCap":2690669302},{"date":"2024-12-13","current":28.10024,"twenty":8.550153,"median":10.241149,"eighty":13.941658,"marketCap":2650217921},{"date":"2024-12-20","current":25.789683,"twenty":8.550153,"median":10.241149,"eighty":14.183552,"marketCap":2432302415},{"date":"2024-12-27","current":26.509138,"twenty":8.550153,"median":10.241149,"eighty":14.332934,"marketCap":2500156345},{"date":"2025-01-03","current":25.734341,"twenty":8.550153,"median":10.241149,"eighty":14.482787,"marketCap":2427082882},{"date":"2025-01-10","current":25.720505,"twenty":8.549794,"median":10.239653,"eighty":14.532851,"marketCap":2425777998},{"date":"2025-01-17","current":26.619823,"twenty":8.549794,"median":10.239653,"eighty":14.674786,"marketCap":2510595411},{"date":"2025-01-24","current":26.24626,"twenty":8.549794,"median":10.239653,"eighty":14.756709,"marketCap":2475363563},{"date":"2025-01-31","current":20.963976,"twenty":8.549794,"median":10.239653,"eighty":14.865144,"marketCap":2421863349},{"date":"2025-02-07","current":22.127386,"twenty":8.549794,"median":10.239653,"eighty":14.930454,"marketCap":2556266325},{"date":"2025-02-14","current":21.3819,"twenty":8.549794,"median":10.239653,"eighty":15.030776,"marketCap":2470144030},{"date":"2025-02-21","current":20.6703,"twenty":8.549794,"median":10.239653,"eighty":15.049841,"marketCap":2387936384},{"date":"2025-02-28","current":20.24108,"twenty":8.549794,"median":10.239653,"eighty":15.119808,"marketCap":2338350819},{"date":"2025-03-07","current":19.574836,"twenty":8.549435,"median":10.238158,"eighty":15.219892,"marketCap":2261382913},{"date":"2025-03-14","current":18.818048,"twenty":8.556094,"median":10.256731,"eighty":15.427951,"marketCap":2173954953},{"date":"2025-03-21","current":19.168203,"twenty":8.563982,"median":10.270461,"eighty":15.642559,"marketCap":2214406696},{"date":"2025-03-28","current":19.642608,"twenty":8.589386,"median":10.284192,"eighty":15.976834,"marketCap":2269212283},{"date":"2025-04-04","current":18.08385,"twenty":8.61897,"median":10.295948,"eighty":16.156501,"marketCap":2089136782},{"date":"2025-04-11","current":16.76376,"twenty":8.629342,"median":10.308893,"eighty":16.250162,"marketCap":1936633430},{"date":"2025-04-17","current":17.215614,"twenty":8.672243,"median":10.320508,"eighty":16.320056,"marketCap":1988833792},{"date":"2025-04-25","current":14.956124,"twenty":8.693028,"median":10.339114,"eighty":16.512412,"marketCap":2205594545},{"date":"2025-04-28","current":14.654875,"twenty":8.695921,"median":10.357421,"eighty":16.512412,"marketCap":2161169063}],"updateTime":1745980452749}}}